Continued">Continued">Continued">A recent 57357 study published in Cancer Biomarkers Journal supporting the use of miRNA-375 as a timely non-invasive effective biomarker for AML diagnosis – Children Cancer Hospital Egypt 57357
  • 19057

A recent 57357 study published in Cancer Biomarkers Journal supporting the use of miRNA-375 as a timely non-invasive effective biomarker for AML diagnosis

    Pursuing to ease burden on patients and families and save time and resources, Hospital 57357’s published a recent research titled“miR-370 is better than miR-375 as a non-invasive diagnostic biomarker for pediatric acute myeloid leukemia patients“ in Cancer Biomarkers Journal on January 21, 2022 Timely diagnosis is crucial for disease management, and in the case acute … Continued

Pursuing to ease burden on patients and families and save time and resources, Hospital 57357’s published a recent research titled“miR-370 is better than miR-375 as a non-invasive diagnostic biomarker for pediatric acute myeloid leukemia patients“ in Cancer Biomarkers Journal on January 21, 2022

Timely diagnosis is crucial for disease management, and in the case acute myeloid leukemia (AML), this typically involves using a bone marrow sample. Obtaining such a sample involves an invasive process, requiring trained medical personnel. This makes the identification of effective non-invasive diagnostic markers for AML of great value with respect to both patient comfort and speed of diagnosis. This study evaluated and compared the use of two potential blood biomarkers, miRNA-370 and miRNA-375, for diagnosis of AML. The results support the potential role of miRNA-370 for effective diagnosis of AML, which is a valuable step to early identification of the disease